Packard Center News
Sep 14
2020
In a new study, a team of Packard scientists identified a key intersection between two major pathways of pathology in ALS and frontotemporal dementia (FTD)
Read the full article in Science Translational Medicine
Sep 3
2020
Results of a new Phase 2 randomized clinical trial in 137 patients with ALS showed that treatment with the drugs sodium phenylbutyrate and taurursodiol, combined together, could significantly slow functional decline over 24 weeks compared to placebo.
Read more about the trial in a recent article on www.nytimes.com
Jul 9
2020
In a new study, Packard scientist Jiou Wang and colleagues showed that RNA structures called G-quadruplexes play a role in the formation and function of a type of granule called a paraspeckle.
Click here to read the full study:
Jun 3
2020
Neuroscientists at Thomas Jefferson University have identified a new way that repeat expansion in the C9orf72 gene—the most common genetic cause of ALS and FTD—can contribute to ALS.
Read the full journal article here
May 8
2020
A new set of Answer ALS project data is now available through the Answer ALS Data Portal
To search the data, please visit the Answer ALS Data Portal!
Mar 26
2020
Due to COVID-19, the annual Fiesta 5k for ALS Research will now be a virtual event!
Visit the Fiesta 5K website today:
Sep 27
2019
Washington College's Phi Delta Theta fraternity hosts annual crab feast to benefit the Packard Center
Read the full article online:
Jun 17
2019
Packard Center founder and director Jeff Rothstein appeared on WYPR to discuss the Answer ALS research program.
To listen to the interview:
Apr 18
2019
Innovative new research from Packard investigators explores how RNA binding proteins might lead to ALS.
Jan 14
2019
A new Packard study found that found that excitotoxic stress and hyperactivity in neurons increased the production of toxic peptides associated with the C9orf72 repeat expansion.
